ATE365051T1 - Stabilisierung von rapamycinen oder rapamycinderivaten - Google Patents

Stabilisierung von rapamycinen oder rapamycinderivaten

Info

Publication number: ATE365051T1
Authority: AT; Austria
Prior art keywords: rapamycins; stabilization; rapamycin derivatives; rapamycin; derivatives
Prior art date: 1998-12-07

Application number

AT99959381T

Other languages

English (en)

Inventor

Francois Navarro

Samuel Petit

Guy Stone

Original Assignee

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-07

Filing date

1999-12-06

Publication date

2007-07-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE365051(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-12-06 Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh

2007-07-15 Application granted granted Critical

2007-07-15 Publication of ATE365051T1 publication Critical patent/ATE365051T1/de

Links

QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
230000006641 stabilisation Effects 0.000 title 1
238000011105 stabilization Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)

AT99959381T 1998-12-07 1999-12-06 Stabilisierung von rapamycinen oder rapamycinderivaten ATE365051T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9826882.4A GB9826882D0 (en)	1998-12-07	1998-12-07	Organic compounds
GBGB9904934.8A GB9904934D0 (en)	1998-12-07	1999-03-04	Organic compounds

Publications (1)

Publication Number	Publication Date
ATE365051T1 true ATE365051T1 (de)	2007-07-15

Family

ID=26314797

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99959381T ATE365051T1 (de)	1998-12-07	1999-12-06	Stabilisierung von rapamycinen oder rapamycinderivaten

Country Status (38)

Country	Link
US (5)	US6605613B2 (de)
EP (4)	EP2279751A3 (de)
JP (3)	JP3805625B2 (de)
KR (2)	KR100695834B1 (de)
CN (2)	CN1261163C (de)
AR (3)	AR026102A1 (de)
AT (1)	ATE365051T1 (de)
AU (1)	AU759219B2 (de)
BE (1)	BE1012869A3 (de)
BR (1)	BR9915986A (de)
CA (3)	CA2351580C (de)
CO (1)	CO4980847A1 (de)
CY (1)	CY1106870T1 (de)
CZ (2)	CZ303006B6 (de)
DE (1)	DE69936352T3 (de)
DK (1)	DK1137439T4 (de)
ES (1)	ES2288033T5 (de)
FR (1)	FR2786771B1 (de)
GB (2)	GB9826882D0 (de)
HK (1)	HK1038889B (de)
HU (2)	HU228939B1 (de)
ID (1)	ID29250A (de)
IL (1)	IL143092A0 (de)
IT (1)	IT1319701B1 (de)
MY (2)	MY127579A (de)
NO (2)	NO332698B1 (de)
NZ (2)	NZ511936A (de)
PE (1)	PE20001333A1 (de)
PL (2)	PL208854B1 (de)
PT (1)	PT1137439E (de)
RU (1)	RU2243769C2 (de)
SG (1)	SG151072A1 (de)
SI (1)	SI1137439T2 (de)
SK (2)	SK286688B6 (de)
TR (2)	TR200101416T2 (de)
TW (2)	TWI270550B (de)
WO (1)	WO2000033878A2 (de)
ZA (1)	ZA200104360B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070032853A1 (en)	2002-03-27	2007-02-08	Hossainy Syed F	40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7452692B2 (en)	2002-02-13	2008-11-18	Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság	Method for extracting a macrolide from biomatter
MXPA04007847A (es)	2002-02-13	2005-02-24	Biogal Gyogyszergyar	Metodo para extraer un macrolido de biomateria.
NZ537829A (en)	2002-07-30	2006-09-29	Wyeth Corp	Parenteral formulations containing a rapamycin hydroxyester
TR200500302T3 (tr) *	2003-03-31	2005-04-21	Biogal Gyogyszergyar Rt.	Makrolidlerin kristalizasyonu ve saflaştırılması.
US20050118344A1 (en)	2003-12-01	2005-06-02	Pacetti Stephen D.	Temperature controlled crimping
TW200523266A (en)	2003-07-24	2005-07-16	Biogal Gyogyszergyar	Method of purifying macrolides
CA2539324A1 (en)	2003-09-18	2005-03-31	Macusight, Inc.	Transscleral delivery
US9114198B2 (en) *	2003-11-19	2015-08-25	Advanced Cardiovascular Systems, Inc.	Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
CN1889994A (zh) *	2003-12-10	2007-01-03	艾克若克斯Dds有限公司	伴随透皮或局部药物输送的不希望的效果的治疗方法
US8551512B2 (en)	2004-03-22	2013-10-08	Advanced Cardiovascular Systems, Inc.	Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
US20060094744A1 (en) *	2004-09-29	2006-05-04	Maryanoff Cynthia A	Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
JP4974903B2 (ja)	2005-02-09	2012-07-11	参天製薬株式会社	疾患または状態を処置するための液体処方物
BRPI0619592A2 (pt) *	2005-12-07	2016-09-06	Wyeth Corp	métodos para medir a qualidade da partícula de um composto de rapamicina, para determinar o tamanho de partícula médio de uma amostra e a cristalinidade de um composto de rapamicina, e para a purificação de rapamicina
US7700614B2 (en) *	2005-12-14	2010-04-20	Abbott Laboratories	One pot synthesis of tetrazole derivatives of rapamycin
RU2008121713A (ru) *	2005-12-20	2010-01-27	Вайет (Us)	Контроль стабильности лекарственной формы cci-779 посредством контроля примесей лекарственныхого вещества
WO2007092620A2 (en) *	2006-02-09	2007-08-16	Macusight, Inc.	Stable formulations, and methods of their preparation and use
PL2001466T3 (pl)	2006-03-23	2016-06-30	Santen Pharmaceutical Co Ltd	Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
WO2011151704A2 (en)	2010-06-02	2011-12-08	Fresenius Kabi Oncology Ltd.	Stable pharmaceutical compositions of rapamycin esters
WO2011156025A1 (en) *	2010-06-07	2011-12-15	Telik, Inc.	Crystalline Ezatiostat Hydrochloride Ansolvate
EP2601201B1 (de) *	2010-08-04	2014-09-24	Meril Life Sciences Pvt. Ltd.	Verfahren zur herstellung von neuen 42-o-(heteroalkoxalkyl) rapamycin verbindungen mit antiproliferativen eigenschaften.
WO2012066502A1 (en)	2010-11-19	2012-05-24	Biocon Limited	Processes for preparation of everolimus and intermediates thereof
JP2014516075A (ja)	2011-06-06	2014-07-07	シェブロンフィリップスケミカルカンパニーエルピー	癌治療のためのメタロセン化合物の使用
WO2013022201A1 (en) *	2011-08-11	2013-02-14	Dong-A Pharm. Co., Ltd.	Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
US9610385B2 (en)	2013-03-07	2017-04-04	Abbott Cardiovascular Systems Inc.	Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (de)	2013-07-31	2015-06-26	Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) *	2013-12-24	2018-01-30	正大天晴药业集团股份有限公司	一种稳定的依维莫司片剂
CN104892632B (zh) *	2015-06-03	2017-12-26	道中道（菏泽）制药有限公司	一种晶体形式的依维莫司及其制备方法
US10383860B2 (en)	2015-07-28	2019-08-20	Nippon Kayaku Kabushiki Kaisha	Pharmaceutical composition comprising rapamycin or derivative thereof, and method for producing the same
JP6793651B2 (ja) *	2015-08-28	2020-12-02	日本化薬株式会社	ラパマイシン又はその誘導体を含有する医薬組成物
WO2017047618A1 (ja) *	2015-09-18	2017-03-23	日本化薬株式会社	ラパマイシン又はその誘導体を含有する医薬組成物
WO2017129772A1 (en)	2016-01-29	2017-08-03	Xellia Phamaceuticals Aps	Stable pharmaceutical compositions of temsirolimus
JP6855470B2 (ja)	2016-05-27	2021-04-07	日本化薬株式会社	ラパマイシン又はその誘導体を含有する医薬組成物
KR102051806B1 (ko) *	2018-01-12	2019-12-04	주식회사 종근당	에베로리무스를 포함하는 안정화된 약제학적 제제
CN119431400A (zh) *	2020-03-27	2025-02-14	波士顿科学国际有限公司	用于使药物结晶的方法
JP2023028473A (ja) *	2021-08-19	2023-03-03	日本マイクロバイオファーマ株式会社	エベロリムスの製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en) *	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US3996355A (en)	1975-01-02	1976-12-07	American Home Products Corporation	Permanent suspension pharmaceutical dosage form
US4049128A (en)	1976-11-18	1977-09-20	Westinghouse Air Brake Company	Control system for automatic railway car coupler
AU543727B2 (en) *	1980-06-02	1985-05-02	Ayerst Mckenna & Harrison Inc.	Injectable composition of rapamycin
CA1338150C (en) †	1988-02-18	1996-03-12	Edward George Howard, Jr.	Ceramic/distillable binder compositions
GB8803836D0 (en)	1988-02-18	1988-03-16	Glaxo Group Ltd	Compositions
KR0159766B1 (ko) *	1989-10-16	1998-12-01	후지사와 토모키치로	양모제 조성물
JPH04230389A (ja) *	1990-07-16	1992-08-19	American Home Prod Corp	ラパマイシン誘導体
FI97472C (fi)	1991-05-07	1996-12-27	American Home Prod	Menetelmä terapeuttisesti käyttökelpoisten rapamysiinijohdannaisten valmistamiseksi anti-inflammatorisina ja antifungaalisina aineina
GB9221220D0 (en) *	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
US5302584A (en) *	1992-10-13	1994-04-12	American Home Products Corporation	Carbamates of rapamycin
EP1266900A1 (de)	1992-10-13	2002-12-18	Wyeth	Carbamate von Rapamycin
RU2181054C2 (ru) *	1994-11-02	2002-04-10	Новартис Аг	Микроэмульсионный предконцентрат
EP0833828B1 (de)	1995-06-09	2002-11-20	Novartis AG	Rapamycinderivate
BE1009856A5 (fr) *	1995-07-14	1997-10-07	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
EP1208847B8 (de) *	1996-07-30	2007-02-14	Novartis AG	Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände
US6362264B1 (en) *	1996-12-20	2002-03-26	Ck Witco Corporation	Stabilizer for food contact and medical grade PVC
WO1998033482A1 (en)	1997-02-04	1998-08-06	Abbott Laboratories	Pain reducing parenteral liposome formulation

1998
- 1998-12-07 GB GBGB9826882.4A patent/GB9826882D0/en not_active Ceased
1999
- 1999-03-04 GB GBGB9904934.8A patent/GB9904934D0/en not_active Ceased
- 1999-11-29 CO CO99074905A patent/CO4980847A1/es unknown
- 1999-12-02 IT IT1999MI002520A patent/IT1319701B1/it active
- 1999-12-03 AR ARP990106171A patent/AR026102A1/es active IP Right Grant
- 1999-12-03 PE PE1999001209A patent/PE20001333A1/es not_active IP Right Cessation
- 1999-12-03 FR FR9915256A patent/FR2786771B1/fr not_active Expired - Lifetime
- 1999-12-04 TW TW094104943A patent/TWI270550B/zh not_active IP Right Cessation
- 1999-12-04 TW TW088121250A patent/TWI248938B/zh not_active IP Right Cessation
- 1999-12-06 SG SG200302502-0A patent/SG151072A1/en unknown
- 1999-12-06 CA CA2351580A patent/CA2351580C/en not_active Expired - Lifetime
- 1999-12-06 TR TR2001/01416T patent/TR200101416T2/xx unknown
- 1999-12-06 AU AU16573/00A patent/AU759219B2/en not_active Expired
- 1999-12-06 JP JP2000586368A patent/JP3805625B2/ja not_active Expired - Lifetime
- 1999-12-06 KR KR1020017007009A patent/KR100695834B1/ko not_active Expired - Lifetime
- 1999-12-06 KR KR1020067017352A patent/KR20060096477A/ko not_active Ceased
- 1999-12-06 RU RU2001118266/15A patent/RU2243769C2/ru active
- 1999-12-06 EP EP10179096A patent/EP2279751A3/de not_active Withdrawn
- 1999-12-06 HK HK02100663.4A patent/HK1038889B/en not_active IP Right Cessation
- 1999-12-06 ID IDW00200101156A patent/ID29250A/id unknown
- 1999-12-06 ES ES99959381T patent/ES2288033T5/es not_active Expired - Lifetime
- 1999-12-06 CA CA2732620A patent/CA2732620C/en not_active Expired - Lifetime
- 1999-12-06 HU HU0104489A patent/HU228939B1/hu unknown
- 1999-12-06 SK SK766-2001A patent/SK286688B6/sk not_active IP Right Cessation
- 1999-12-06 WO PCT/EP1999/009521 patent/WO2000033878A2/en not_active Ceased
- 1999-12-06 CZ CZ20012001A patent/CZ303006B6/cs not_active IP Right Cessation
- 1999-12-06 BR BR9915986-4A patent/BR9915986A/pt not_active Application Discontinuation
- 1999-12-06 CZ CZ20050170A patent/CZ302210B6/cs not_active IP Right Cessation
- 1999-12-06 EP EP06122628A patent/EP1743657A3/de not_active Ceased
- 1999-12-06 TR TR2002/01428T patent/TR200201428T2/xx unknown
- 1999-12-06 PL PL380082A patent/PL208854B1/pl unknown
- 1999-12-06 IL IL14309299A patent/IL143092A0/xx not_active IP Right Cessation
- 1999-12-06 SI SI9930985T patent/SI1137439T2/sl unknown
- 1999-12-06 EP EP10179099A patent/EP2269651A3/de not_active Withdrawn
- 1999-12-06 AT AT99959381T patent/ATE365051T1/de active
- 1999-12-06 DE DE69936352T patent/DE69936352T3/de not_active Expired - Lifetime
- 1999-12-06 PL PL348333A patent/PL196627B1/pl unknown
- 1999-12-06 CA CA002651609A patent/CA2651609A1/en not_active Abandoned
- 1999-12-06 HU HU1300289A patent/HU230174B1/hu unknown
- 1999-12-06 SK SK5032-2008A patent/SK287325B6/sk not_active IP Right Cessation
- 1999-12-06 EP EP99959381A patent/EP1137439B2/de not_active Expired - Lifetime
- 1999-12-06 CN CNB998141240A patent/CN1261163C/zh not_active Expired - Lifetime
- 1999-12-06 CN CN2006100798040A patent/CN1876657B/zh not_active Expired - Lifetime
- 1999-12-06 DK DK99959381.7T patent/DK1137439T4/da active
- 1999-12-06 NZ NZ511936A patent/NZ511936A/en not_active IP Right Cessation
- 1999-12-06 PT PT99959381T patent/PT1137439E/pt unknown
- 1999-12-07 BE BE9900799A patent/BE1012869A3/fr not_active IP Right Cessation
- 1999-12-07 MY MYPI20043386A patent/MY127579A/en unknown
- 1999-12-07 MY MYPI99005309A patent/MY120594A/en unknown
2001
- 2001-05-16 NO NO20012424A patent/NO332698B1/no not_active IP Right Cessation
- 2001-05-28 ZA ZA200104360A patent/ZA200104360B/en unknown
- 2001-05-29 US US09/866,977 patent/US6605613B2/en not_active Expired - Lifetime
2003
- 2003-03-21 US US10/393,795 patent/US6852729B2/en not_active Expired - Lifetime
- 2003-08-25 NZ NZ527781A patent/NZ527781A/en not_active IP Right Cessation
2004
- 2004-12-23 US US11/020,860 patent/US7297703B2/en not_active Expired - Lifetime
2005
- 2005-02-28 AR ARP050100744A patent/AR048073A2/es active IP Right Grant
- 2005-04-01 JP JP2005106512A patent/JP5043308B2/ja not_active Expired - Lifetime
- 2005-12-28 JP JP2005378514A patent/JP5165199B2/ja not_active Expired - Lifetime
2006
- 2006-05-04 AR ARP060101807A patent/AR054444A2/es active IP Right Grant
2007
- 2007-09-14 CY CY20071101192T patent/CY1106870T1/el unknown
- 2007-10-11 US US11/973,927 patent/US7572804B2/en not_active Expired - Fee Related
2009
- 2009-07-06 US US12/497,728 patent/US7741338B2/en not_active Expired - Fee Related
2012
- 2012-10-01 NO NO20121113A patent/NO334612B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
ITMI992520A1 (it)	2001-06-02
BE1012869A3 (fr)	2001-04-03
ES2288033T3 (es)	2007-12-16
US7572804B2 (en)	2009-08-11
SI1137439T2 (sl)	2012-05-31
GB9904934D0 (en)	1999-04-28
ITMI992520A0 (it)	1999-12-02
AU1657300A (en)	2000-06-26
JP2006111637A (ja)	2006-04-27
HUP0104489A3 (en)	2004-05-28
FR2786771A1 (fr)	2000-06-09
PE20001333A1 (es)	2000-12-12
PT1137439E (pt)	2007-09-25
CZ303006B6 (cs)	2012-02-22
NO20012424D0 (no)	2001-05-16
WO2000033878A3 (en)	2000-11-02
WO2000033878A2 (en)	2000-06-15
CA2732620A1 (en)	2000-06-15
IL143092A0 (en)	2002-04-21
US7741338B2 (en)	2010-06-22
FR2786771B1 (fr)	2002-12-27
AR048073A2 (es)	2006-03-29
EP2269651A2 (de)	2011-01-05
RU2243769C2 (ru)	2005-01-10
TR200101416T2 (tr)	2002-01-21
JP2002531527A (ja)	2002-09-24
NO20012424L (no)	2001-05-16
CZ20012001A3 (cs)	2001-09-12
ID29250A (id)	2001-08-16
NO20121113L (no)	2001-05-16
US20050107418A1 (en)	2005-05-19
CY1106870T1 (el)	2012-09-26
DK1137439T3 (da)	2007-09-10
US20030191148A1 (en)	2003-10-09
PL348333A1 (en)	2002-05-20
CN1876657B (zh)	2013-01-09
EP2279751A3 (de)	2011-02-16
US6605613B2 (en)	2003-08-12
CA2351580C (en)	2012-03-20
TWI270550B (en)	2007-01-11
US20090270441A1 (en)	2009-10-29
EP1743657A3 (de)	2007-03-28
US6852729B2 (en)	2005-02-08
GB9826882D0 (en)	1999-01-27
TW200540179A (en)	2005-12-16
JP3805625B2 (ja)	2006-08-02
SI1137439T1 (sl)	2008-06-30
US20080161334A1 (en)	2008-07-03
EP2279751A2 (de)	2011-02-02
BR9915986A (pt)	2001-09-04
EP1137439A2 (de)	2001-10-04
MY120594A (en)	2005-11-30
DE69936352T2 (de)	2008-02-14
ES2288033T5 (es)	2012-04-10
CO4980847A1 (es)	2000-11-27
PL196627B1 (pl)	2008-01-31
HK1038889A1 (en)	2002-04-04
US7297703B2 (en)	2007-11-20
ZA200104360B (en)	2002-01-16
CZ302210B6 (cs)	2010-12-22
EP1743657A2 (de)	2007-01-17
TWI248938B (en)	2006-02-11
HU228939B1 (en)	2013-07-29
EP1137439B1 (de)	2007-06-20
TR200201428T2 (tr)	2002-12-23
AR026102A1 (es)	2003-01-29
NO334612B1 (no)	2014-04-22
HU230174B1 (hu)	2015-09-28
NZ527781A (en)	2004-11-26
KR20010101128A (ko)	2001-11-14
CA2351580A1 (en)	2000-06-15
JP5043308B2 (ja)	2012-10-10
HUP0104489A2 (hu)	2002-03-28
CN1876657A (zh)	2006-12-13
JP2005200429A (ja)	2005-07-28
CN1374872A (zh)	2002-10-16
SK286688B6 (sk)	2009-03-05
JP5165199B2 (ja)	2013-03-21
EP1137439B2 (de)	2011-11-23
CA2651609A1 (en)	2000-06-15
AR054444A2 (es)	2007-06-27
SK287325B6 (sk)	2010-07-07
DK1137439T4 (da)	2012-03-19
SK7662001A3 (en)	2001-12-03
PL208854B1 (pl)	2011-06-30
MY127579A (en)	2006-12-29
KR100695834B1 (ko)	2007-03-19
DE69936352D1 (de)	2007-08-02
AU759219B2 (en)	2003-04-10
CN1261163C (zh)	2006-06-28
US20020032213A1 (en)	2002-03-14
NZ511936A (en)	2003-10-31
KR20060096477A (ko)	2006-09-11
SG151072A1 (en)	2009-06-29
CA2732620C (en)	2013-08-06
EP2269651A3 (de)	2011-03-09
DE69936352T3 (de)	2012-05-03
IT1319701B1 (it)	2003-10-27
HK1038889B (en)	2008-01-25
NO332698B1 (no)	2012-12-10

Legal Events

Date

Code

Title

Description

2007-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1137439

Country of ref document: EP

Publication	Publication Date	Title
ATE365051T1 (de)	2007-07-15	Stabilisierung von rapamycinen oder rapamycinderivaten
FI962487A7 (fi)	1996-06-14	Rapamysiinijohdannaisia
ATE222256T1 (de)	2002-08-15	Polymorphe form von clopidogrel-hydrogenosulfat
ID29021A (id)	2001-07-26	Komposisi galantamina pelepasan terkontrol
DK1384478T3 (da)	2011-05-23	Antibiotiske sammensætninger indeholdende moxifloxacin til behandling af øjet
ID16866A (id)	1997-11-20	Kompleks kompleks inklusi garam-garam aril-heterosiklik
DK0833828T3 (da)	2003-03-17	Rapamycinderivater
PT950059E (pt)	2004-10-29	Derivados de sulfona ciclicos
DE69332540D1 (de)	2003-01-16	Rapamycinderivate
DE69332484D1 (de)	2002-12-19	Rapamycinderivate
PT945132E (pt)	2004-08-31	Composicao de ibuprofeno
DE60028307D1 (de)	2006-07-06	Eliminierung von interferenzsignalen
DE69922494D1 (de)	2005-01-13	Zyklische n-acylamin-derivate
PT946512E (pt)	2004-01-30	Derivados de 6-fenilpiridil-2-amina uteis como inibidores de nos
DE50010774D1 (de)	2005-08-25	Anlage zur bearbeitung von wafern
LV12167A (lv)	1998-11-20	Jauni makrocikliski savienojumi ka metalproteinazes inhibitori
PT1100326E (pt)	2003-08-29	Microcapsulas de libertacao activada por bases
DE50013866D1 (de)	2007-01-25	Anlage zur bearbeitung von wafern
DE50013163D1 (de)	2006-08-24	Anlage zur bearbeitung von wafern
DE69332582D1 (de)	2003-01-30	Rapamycinderivate
DE69903143D1 (de)	2002-10-31	Chromanon und thiochromanon derivate
DK1300129T3 (da)	2005-06-20	Implantathætteglas
PT869121E (pt)	2004-10-29	Derivados de propanolamina hipolipidemicos
PT1140924E (pt)	2006-08-31	Derivados de piperazina
PT1237856E (pt)	2004-08-31	Novos derivados fenilicos tri-substituidos e analogos